Tag: Medtronic

Medtronic names Laura Mauri as new chief scientific, medical and regulatory...

Medtronic has announced that Laura Mauri has been appointed as the company’s chief scientific, medical and regulatory officer. This appointment adds to Mauri's prior responsibilities...

Abre venous stent “remains safe and effective” out to 24 months,...

The Abre venous stent (Medtronic) remains safe and effective for the treatment of iliofemoral venous obstructive disease out to 24 months. This is according...
VenaSeal

Five-year, single-centre VenaSeal outcomes for symptomatic saphenous incompetence revealed

Morwan Bahi (Wellington Regional Hospital, Wellington, New Zealand) presented five-year results of a retrospective, observational, single-centre study detailing outcomes for all patients with symptomatic...

ABRE study meets primary safety and effectiveness endpoints

Medtronic has announced the first-ever results from the ABRE clinical study assessing the safety and effectiveness of the investigational Abre venous self-expanding stent system...

Omar Ishrak to step down as Medtronic CEO next year

Omar Ishrak, Medtronic’s chairman and CEO is to retire on 26 April 2020, following the end of the company’s current fiscal year. Also, the...

Non-thermal techniques for treatment of venous ulcers: Off-label use of cyanoacrylate...

At the American Venous Forum (AVF; 20–23 February, Tucson, USA), a session on venous leg ulcers turned to possible future treatment strategies as Kathleen...
Abre

IDE study to evaluate Abre Venous Self-Expanding Stent in patients with...

Medtronic has announced the initiation of its investigational device exemption (IDE) study for the Abre venous self-expanding stent system. The ABRE IDE Study will...
VenaSeal

Medtronic receives favourable CMS ruling on VenaSeal

The US Centers for Medicare and Medicaid Services (CMS) has posted the 2018 Medicare Physician Fee Schedule (CMS-1678-F) and Hospital Outpatient Prospective Payment and...

Medtronic launches Concerto 3D detachable coil system in USA and Europe

Medtronic is expanding its embolisation product portfolio with the launch of the Concerto 3D detachable coil system. The system was launched at the Cardiovascular...

Adhesive closure “an effective add-on” to thermal ablation

Endovenous adhesive closure systems are a useful adjunct to thermal ablation treatment for varicose veins, but it is vital that the possible side-effects of...

VeClose trial indicates 24-month non-inferiority of VenaSeal versus radiofrequency ablation

Two-year outcomes of the VeClose pivotal trial have been reported, showing a 94.3% closure rate and “continued non-inferiority results to radiofrequency ablation” when using...

WAVES trial shows 100% vein closure at one month with short...

A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life...